Natus Medical (NASDAQ:BABY)‘s stock had its “buy” rating reiterated by research analysts at Benchmark in a research report issued on Tuesday, Marketbeat.com reports. They currently have a $49.00 target price on the medical equipment provider’s stock, down from their prior target price of $55.00. Benchmark’s price target would suggest a potential upside of 70.14% from the company’s current price.

BABY has been the subject of several other reports. BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. Zacks Investment Research raised Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Finally, William Blair cut Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $47.00.

Shares of Natus Medical (NASDAQ BABY) traded down $0.15 during midday trading on Tuesday, hitting $28.80. The stock had a trading volume of 792,300 shares, compared to its average volume of 1,159,860. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. Natus Medical has a one year low of $28.25 and a one year high of $43.60. The company has a market cap of $897.24, a P/E ratio of -480.00 and a beta of 0.84.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.02. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The company had revenue of $122.60 million during the quarter, compared to the consensus estimate of $122.41 million. During the same period in the previous year, the company posted $0.39 EPS. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year. equities analysts predict that Natus Medical will post 1.64 EPS for the current fiscal year.

In other Natus Medical news, Director William M. Moore sold 5,000 shares of Natus Medical stock in a transaction on Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of Natus Medical stock in a transaction on Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the transaction, the vice president now directly owns 141,414 shares of the company’s stock, valued at $6,068,074.74. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in BABY. Benjamin F. Edwards & Company Inc. raised its holdings in Natus Medical by 2,085.6% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock valued at $102,000 after acquiring an additional 2,607 shares in the last quarter. Riverhead Capital Management LLC raised its holdings in Natus Medical by 90.9% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after acquiring an additional 1,364 shares in the last quarter. SG Americas Securities LLC acquired a new position in Natus Medical in the 3rd quarter valued at $138,000. Victory Capital Management Inc. raised its holdings in Natus Medical by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock valued at $140,000 after acquiring an additional 560 shares in the last quarter. Finally, Flinton Capital Management LLC raised its holdings in Natus Medical by 82.0% in the 2nd quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 1,700 shares in the last quarter. 99.87% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/16/benchmark-lowers-natus-medical-baby-price-target-to-49-00.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.